Anticoagulation with heparin increases survival in moderately-ill COVID-19 patients: NEJM
Treating moderately ill hospitalized COVID-19 patients with therapeutic-dose anticoagulation with heparin increased the probability of survival.
USA: An initial strategy of therapeutic-dose anticoagulation with heparin in noncritically ill patients with Covid-19 increases the chances of survival, according to a recent study. The strategy also reduced the use of cardiovascular or respiratory organ support versus usual-care thromboprophylaxis.
The international study, published in the New England Journal of Medicine, involved 121 sites, including UT Southwestern Medical Center.
Moderately ill COVID-19 patients treated with therapeutic-dose anticoagulation with unfractionated or low molecular-weight heparin were 27% less likely to need cardiovascular respiratory organ support such as intubation, said Ambarish Pandey, M.D., Assistant Professor of Internal Medicine at UT Southwestern, who served as site investigator and co-author of the study. Moderately ill patients had a 4% increased chance of survival until discharge without requiring organ support with anticoagulants, according to the study involving 2,200 patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.